Stemline Therapeutics (STML) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts STML Hot Sheet
Join SI Premium – FREE
Stemline Therapeutics (NASDAQ: STML) reported Q1 EPS of ($0.46), $0.01 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $121.4 thousand versus the consensus estimate of $50 thousand.
For earnings history and earnings-related data on Stemline Therapeutics (STML) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Top AI Semiconductor Stocks According to Stifel Analysis
- Helen of Troy (HELE) PT Raised to $29 at UBS on Q2 Beat
- Amrize Ltd (AMRZ) PT Lowered to $40 at DA Davidson as FY26 Guidance 'at Risk'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
